← Oncology Approval Tracker

FDA DECISION ·

Braftovi + cetuximab + chemotherapy

encorafenib with cetuximab and fluorouracil-based chemotherapy · Array BioPharma / Pfizer

Traditional approvalTraditional conversionColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic colorectal cancer and a BRAF V600E mutation identified by an FDA-authorized test.

LAMPGEN ANALYSIS

Why it matters

The decision converts accelerated approval and supports a fluorouracil-based chemotherapy backbone. BREAKWATER evaluated the targeted combination in treatment-naïve metastatic disease.

What research teams should watch

Confirm the exact BRAF alteration and chemotherapy backbone. Trial teams should reassess comparator relevance where the first-line treatment landscape changes.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Molecularly selected metastatic disease

PRIMARY RECORDS

Sources